Jingdong Chao
Overview
Explore the profile of Jingdong Chao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
2567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simpson E, Eckert L, Gadkari A, Brown T, A Lio P, Lockshin B, et al.
Br J Dermatol
. 2024 Apr;
190(6):917-919.
PMID: 38593196
No abstract available.
2.
Paller A, Siegfried E, Marron S, Clark M, DiBenedetti D, Nelson L, et al.
J Am Acad Dermatol
. 2023 Oct;
90(2):382-385.
PMID: 37778662
No abstract available.
3.
Kimball A, Delevry D, Yang M, Chuang C, Wang Z, Bego-Le-Bagousse G, et al.
Dermatol Ther (Heidelb)
. 2023 Aug;
13(9):2107-2120.
PMID: 37552431
Introduction: Atopic dermatitis (AD) can require long-term therapy. Few real-world studies have evaluated long-term effectiveness from the patients' perspective. The aim of this study was to evaluate patient-reported outcomes (PROs)...
4.
Paller A, Yosipovitch G, Weidinger S, DiBenedetti D, Whalley D, Gadkari A, et al.
Dermatol Ther (Heidelb)
. 2022 Oct;
12(12):2839-2850.
PMID: 36269504
Introduction: Itch associated with atopic dermatitis (AD) has a profoundly negative effect on patients of all ages. Therefore, itch is a main target for AD therapeutic approaches, and treatments are...
5.
Yang M, Chao J, Fillbrunn M, Mallya U, Wang M, Franke L, et al.
Patient Prefer Adherence
. 2022 Sep;
16:2649-2661.
PMID: 36176349
Purpose: Multiple biologics are available for moderate to severe asthma. Given the important relationship between patient engagement in healthcare decision-making and health outcomes, patient preference is an increasingly important consideration....
6.
Liu Y, Soderberg J, Chao J
Pharmacy (Basel)
. 2022 Jul;
10(4).
PMID: 35893725
Objectives: (1) to determine the adherence and persistence rates of adalimumab therapy among Swedish patients with Crohn's disease (CD), and (2) to compare self-administration devices to predict the medication adherence...
7.
Zhang Y, Clegg J, Keith S, McFadden S, Symonds T, Kumar R, et al.
J Patient Rep Outcomes
. 2022 May;
6(1):55.
PMID: 35633412
Background: An observer-reported outcome (ObsRO) measure assessing both symptom control and health-related quality of life (HRQoL) in children with asthma younger than 6 years is lacking. The objective of this...
8.
Bagel J, Nguyen T, Lima H, Jain N, Pariser D, Hsu S, et al.
Dermatol Ther (Heidelb)
. 2022 May;
12(6):1417-1430.
PMID: 35590038
Introduction: Dupilumab was initially approved in 2017 as the first biologic therapy for atopic dermatitis (AD). We characterized adults with AD initiating dupilumab in a real-world setting in the USA/Canada....
9.
Canonica G, Bourdin A, Peters A, Desrosiers M, Bachert C, Weidinger S, et al.
J Allergy Clin Immunol Pract
. 2022 Mar;
10(6):1515-1526.
PMID: 35259535
Background: Type 2 inflammatory diseases often coexist in patients. Dupilumab targets type 2 inflammation and has demonstrated treatment benefits in patients with atopic dermatitis (AD), asthma, and chronic rhinosinusitis with...
10.
Bateman E, Khan A, Xu Y, Guyot P, Chao J, Kamat S, et al.
Respir Med
. 2022 Jan;
191:106088.
PMID: 35090691
No abstract available.